참고문헌
- Hesketh PJ, Grunberg SM, Gralla RJ, et al (2003). The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin the Aprepitant Protocol 052 Study Group. J Clin Oncol, 21, 4112-9. https://doi.org/10.1200/JCO.2003.01.095
- McCrea JB, Majumdar AK, Goldberg MR, et al (2003). Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther, 74, 17-24. https://doi.org/10.1016/S0009-9236(03)00066-3
- Roila F, Ruggeri B, Ballatori E, Del Favero A, Tonato M (2014). Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study. J Clin Oncol, 32, 101-6. https://doi.org/10.1200/JCO.2013.51.4547
- Takahashi T, Nakamura Y, Tsuya A, et al (2011). Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients. Cancer Chemother Pharmacol, 68, 653-9. https://doi.org/10.1007/s00280-010-1519-2
- Uchino J, Hirano R, Tashiro N, et al (2012). Efficacy of aprepitant in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy. Asian Pac J Cancer Prev, 13, 4187-90. https://doi.org/10.7314/APJCP.2012.13.8.4187